Jim Simons Evolus, Inc. Transaction History

Renaissance Technologies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$9.99 - $14.91 $2.38 Million - $3.56 Million	-238,700 Reduced 89.84%	27,000 $378,000
Q4 2023 Feb 13, 2024	BUY	$7.6 - $10.53 $1.89 Million - $2.62 Million	248,800 Added 1472.19%	265,700 $2.8 Million
Q3 2023 Nov 14, 2023	SELL	$7.15 - $10.2 $1.04 Million - $1.49 Million	-146,000 Reduced 89.63%	16,900 $154,000
Q2 2023 Aug 11, 2023	SELL	$7.23 - $10.52 $459,314 - $668,325	-63,529 Reduced 28.06%	162,900 $1.18 Million
Q1 2023 May 12, 2023	BUY	$7.81 - $11.05 $1.06 Million - $1.49 Million	135,129 Added 148.01%	226,429 $1.92 Million
Q4 2022 Feb 13, 2023	BUY	$6.52 - $8.95 $595,276 - $817,134	91,300 New	91,300 $686,000
Q2 2022 Aug 12, 2022	BUY	$10.22 - $13.94 $126,728 - $172,856	12,400 New	12,400 $144,000
Q1 2021 May 13, 2021	SELL	$3.2 - $16.51 $811,673 - $4.19 Million	-253,648 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$2.92 - $4.84 $500,777 - $830,055	171,499 Added 208.77%	253,648 $852,000
Q3 2020 Nov 13, 2020	BUY	$3.03 - $5.48 $248,911 - $450,176	82,149 New	82,149 $321,000

168

47.8M

130K

51K

Ticker EOLS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 56,094,800
Market Cap $608M
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.